North America
Tags: Canada, Life SciencesBy Richard Y. Cheung, Ph.D., Toronto, Fasken Martineau DuMoulin
Due to concerns about the growing percentage of the health care budget allotted to drug spending in Canada and the relative drug prices in Canada compared to other developed countries, the Canadian government is proposing changes to the way in which prices for patented drugs are regulated …
Read or download the full article below.
Latest Updates
Related Articles
Related Articles by Jurisdiction
Proposed changes to Canada's anti-money laundering and anti-terrorist financing regime
A consultation paper released in February could potentially have broad implications for Canada's AML/ATF regime.
New transparency registry for all private BC companies in the offing
If the bill comes into force it will have far reaching compliance consequences for all private BC companies.
Drastic changes in the US immigration landscape
The landscape is undergoing drastic changes that all companies and their employees need to understand.
Latest Articles















